Biotechnology

I-Mab Reports Full Year 2023 Financial Results and Business Update

* Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end ofMarch 2024 * Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inh...

2024-03-15 05:00 3428

D3 Bio Appoints Dr. Antoine Yver as Independent Board Member

SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, welcomesAntoine Yver, MD. ,MSc. as the new independent board member, effectiveMarch 4, 2024. Dr. Yver has 34 years of e...

2024-03-14 22:30 1879

Virtus Medical Group Announces New Strategic Investors

Shanghai Healthcare Capital, along with Mitsui and MediTrust, invest in and partner strategically with Virtus, cementing Virtus'sLeadership in Private  Healthcare Services, and Propelling Healthcare Innovation. HONG KONG, March 14, 2024 /PRNewswire/ -- Virtus Medical Holdings Limited ("Virtus Med...

2024-03-14 19:43 3217

European Wellness and Sabah Government to Propel State into World-Class Medical Wellness Tourism Biotech Hub

KOTA KINABALU, Malaysia, March 14, 2024 /PRNewswire/ -- European Wellness, a leading name in health and wellness, announces a groundbreaking collaboration with theSabah state government, aimed at positioning Sabah as a premier destination for medical wellness tourism on the global stage. Chief...

2024-03-14 18:46 3384

Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited (" Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article namedMY...

2024-03-14 12:22 1582

Fapon Empowers Indian IVD Manufacturers at Medical Fair India 2024

DONGGUAN, China, March 14, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, continues its commitment in empowering the Indian IVD industry at Medical Fair India 2024, which is held fromMarch 13 to 15 at Mumbai, India. As one of the most significant medical trade fairs in India,...

2024-03-14 11:35 2603

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024

SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase I clinical study conducted inAustralia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, has b...

2024-03-14 08:39 2029

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering inin vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto inKyoto, Japan. TIDES Asia

2024-03-13 20:00 1514

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience andDartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually onWednesday, March 27, 2024 ( 11:00 AM - 3:30 PM ET). VISTA is a novel immune checkpoint imp...

2024-03-13 17:00 2607

Sanyou Biopharmaceuticals Launches Advanced Intelligent R&D Service Platform

SHANGHAI, March 12, 2024 /PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," representing a transformative advancement in biopharmaceutical research and development. Our platform en...

2024-03-13 09:00 1646

Novel Molecules From Generative AI to Phase II: First Novel TNIK Inhibitors for Fibrotic Diseases Discovered and Designed Using Generative AI

* A study published in Nature Biotechnology presents the entire journey of INS018_055, from AI algorithms to Phase II clinical trials for the first time. * Raw data from 13 preclinical experiments and 3 clinical trials referenced in this study can be accessed by visiting Insilico'sdata room <...

2024-03-13 08:00 2682

Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held inSan Diego, USA, from April 5...

2024-03-12 22:00 1880

GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%

R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...

2024-03-12 20:15 2709

Metabolon and Cardiff University Centre for Neuropsychiatric Genetics and Genomics Forge Alliance to Propel Multiple Sclerosis Research

Partnership will investigate the underlying disease mechanisms of multiple sclerosis (MS) with the potential of finding new relevant drug targets MORRISVILLE, N.C., March 12, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of li...

2024-03-12 20:05 1995

Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, ...

2024-03-12 20:00 1593

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility,...

2024-03-12 20:00 2065

Innovating the Future: ISoOR 2024 Annual Meeting Achieves Remarkable Success

SINGAPORE, March 12, 2024 /PRNewswire/ -- From March 7 to 8, 2024, the International Society of Organoid Research (ISoOR) convened its 2024 annual meeting, after the successful conference inSingapore last year. This year, the conference was held in the vibrant city ofShanghai, China, reflecting t...

2024-03-12 11:57 2033

TFS HealthScience Unveils Asia Pacific Expansion, Elevating Patient Access and Innovation

LUND, Sweden, March 12, 2024 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an operational base in Melbourne, Australia. This strategic move marks a significant m...

2024-03-12 10:52 2020

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmu...

2024-03-12 08:00 2354

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

2024-03-12 08:00 1851
1 ... 47484950515253 ... 306

Week's Top Stories